Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT00556621

Gemcitabine, Cisplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer (GEMCIRAV)

Phase 1-2 Study of the Association of Gemzar ® - Cisplatin-concurrent Radiotherapy in Patients With Non-metastatic Tumors of the Bladder

Sponsor: Groupe D'Etude des Tumeurs Uro-Genitales

Conditions Bladder Cancer

Interventions biopsy cisplatin cystoscopy gemcitabine hydrochloride radiation therapy therapeutic conventional surgery

Updated 5 times since 2017 Last updated: Jul 29, 2015 Started: Jun 30, 2005 Primary completion: Aug 31, 2009 Completion: Aug 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Bladder Cancer, this trial is completed. The trial is conducted by Groupe D'Etude des Tumeurs Uro-Genitales and has accumulated 5 data snapshots since 2005. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

First recorded

Jun 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Groupe D'Etude des Tumeurs Uro-Genitales
Institut du Cancer de Montpellier - Val d'Aurelle

Data source: Institut du Cancer de Montpellier - Val d'Aurelle

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Montpellier, France